Incubation
Seed funding
Seed funding will be utilized to achieve significant de-risking to in vivo proof of concept for Exacis’ first product by validating the following:
-
- Applicability of mRNA-based iPSC generation technology and approach to cancer therapeutics development
- mRNA based combinatorial editing approach, including structure and function of edits
- Clonal aspect of iPSC expansion
- iPSC to ExaCAR-T cell differentiation approach
- Relevance of edit selection toward achievement of immune related goals
- Overall function of cell therapy in an in vivo tumor model
Manufacturing process
Regulatory pathway
Efficient regulatory pathway leveraging multiple accelerated programs in the US and European Union
Capital
Capital efficiency achieved through reproducible approach for application of technologies to develop subsequent products (including NK)
Intellectual Property
Exacis has exclusive rights to a robust patent estate for use in oncology
Market Potential
Multibillion-dollar market potential in the US and EU
Investment and acquisition
Very active investment and acquisition space with more than 5 IPOs in past 24 months
Team
The Future of Cell Therapies
Exacis is developing advanced cellular therapeutics with the aim to deliver potent, targeted, effective cell therapies to harness the human immune system and cure cancer. This is the future.